Prostate cancer screening: what we have learned from the PLCO and ERSPC trials.
about
Predictive value of digital rectal examination for prostate cancer detection is modified by obesityIs prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, CanadaPSA mass screening: is there enough evidence?Smarter screening for prostate cancer: for the few, not the many? A stratified approach based on baseline risk.The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
P2860
Prostate cancer screening: what we have learned from the PLCO and ERSPC trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prostate cancer screening: what we have learned from the PLCO and ERSPC trials.
@en
Prostate cancer screening: what we have learned from the PLCO and ERSPC trials.
@nl
type
label
Prostate cancer screening: what we have learned from the PLCO and ERSPC trials.
@en
Prostate cancer screening: what we have learned from the PLCO and ERSPC trials.
@nl
prefLabel
Prostate cancer screening: what we have learned from the PLCO and ERSPC trials.
@en
Prostate cancer screening: what we have learned from the PLCO and ERSPC trials.
@nl
P1476
Prostate cancer screening: what we have learned from the PLCO and ERSPC trials.
@en
P2093
Christopher L Amling
Jeffrey La Rochelle
P2888
P304
P356
10.1007/S11934-010-0109-5
P577
2010-05-01T00:00:00Z